Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 26, 2017

DrugPatentWatch Database Preview

BROMOCRIPTINE MESYLATE Drug Profile

« Back to Dashboard

What is the patent landscape for Bromocriptine Mesylate, and when can generic versions of Bromocriptine Mesylate launch?

Bromocriptine Mesylate is a drug marketed by Lek Pharm, Mylan, Sandoz Inc, Paddock Llc, and Zydus Pharms Usa Inc. and is included in six NDAs.

The generic ingredient in BROMOCRIPTINE MESYLATE is bromocriptine mesylate. There are nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the bromocriptine mesylate profile page.

Summary for Tradename: BROMOCRIPTINE MESYLATE

Patents:0
Applicants:5
NDAs:6
Suppliers / Packagers: see list9
Bulk Api Vendors: see list36
Clinical Trials: see list184
Patent Applications: see list5,272
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:BROMOCRIPTINE MESYLATE at DailyMed

Pharmacology for Tradename: BROMOCRIPTINE MESYLATE

Ingredient-typeErgolines
Drug ClassErgot Derivative
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lek Pharm
BROMOCRIPTINE MESYLATE
bromocriptine mesylate
CAPSULE;ORAL075100-001Dec 10, 1998DISCNNoNo► Subscribe► Subscribe
Paddock Llc
BROMOCRIPTINE MESYLATE
bromocriptine mesylate
TABLET;ORAL077646-001Oct 1, 2008ABRXNoYes► Subscribe► Subscribe
Mylan
BROMOCRIPTINE MESYLATE
bromocriptine mesylate
CAPSULE;ORAL077226-001Apr 4, 2005ABRXNoYes► Subscribe► Subscribe
Sandoz Inc
BROMOCRIPTINE MESYLATE
bromocriptine mesylate
TABLET;ORAL074631-001Jan 13, 1998ABRXNoNo► Subscribe► Subscribe
Zydus Pharms Usa Inc
BROMOCRIPTINE MESYLATE
bromocriptine mesylate
CAPSULE;ORAL078899-001Jul 30, 2008ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Predict branded drug patent expiration
  • Identify first generic entrants
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot